Clinical trials: tuberculosis
Tuberculosis
Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen
720 cases TB (Tuberculosis patients) participants、360 cases non-TB participants with lung disease and suspected TB patients who all meet the standard are divided into different groups through a randomized and blind method.
- Trial name
- NCT02623556
- Testing
- ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm, ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm
- Where
- 2 sites in China
- Volunteers
- 1,090 people
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Post Pulmonary Tuberculosis, Post-Tuberculous Bronchiectasis
The Feasibility and Acceptability of a Post-tuberculosis Lung Disease Diagnostic Algorithm in Uganda.
The goal of this clinical trial is to determine whether a structured diagnostic algorithm improves the identification and referral of people with post-tuberculosis lung disease (PTLD) in primary healthcare facilities in Uganda.
- Trial name
- IMPULSE (NCT07067528)
- Testing
- A novel PTLD clinical diagnostic algorithm
- Where
- Uganda
- Volunteers
- 80 people
- Sponsor
- Mbarara University of Science and Technology
Latent Tuberculosis, Staphylococcus Aureus
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus…
- Trial name
- NCT05073926
- Testing
- No intervention is part of the study protocol
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Skane
Tuberculosis, Multidrug-Resistant
A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
A phase 2, multicenter, uncontrolled, open-label trial in participants with Multi-drug Resistant Tuberculosis (MDR-TB). Only participants who completed Trial 242-07-204 (NCT00685360) were eligible.
- Trial name
- NCT02573350
- Testing
- Delamanid, OBR
- Where
- 8 sites in China, Estonia and 4 more
- Volunteers
- 213 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
HIV Infection, Tuberculosis
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
There is a rapidly-growing need to identify evidence-based, safe, and effective co-treatment regimens for HIV-related tuberculosis (TB) among patients who require protease inhibitor (PI)-based antiretroviral therapy (ART).
- Trial name
- NCT01601626
- Testing
- Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir
- Where
- 9 sites in Brazil, Haiti and 3 more
- Volunteers
- 71 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Tuberculosis, Severe Acute Malnutrition
Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition (TB-Speed SAM)
TB-Speed SAM is a multicentric, prospective diagnostic cohort study conducted in two countries with high and very high TB incidence (Uganda and Zambia).
- Trial name
- NCT04240990
- Testing
- Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.
- Where
- 3 sites in Uganda, Zambia
- Volunteers
- 603 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
HIV Infections, Tuberculosis
Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
To evaluate and compare the safety and effectiveness of a one-year course of isoniazid (INH) versus a two-month course of rifampin plus pyrazinamide for the prevention of reactivation tuberculosis in individuals infected with…
- Trial name
- NCT00000638
- Testing
- Isoniazid, Pyrazinamide, Pyridoxine hydrochloride
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 2,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Tuberculosis
Ultra-Short Regimen for Elderly DS-TB
Tuberculosis (TB) remains one of the leading global public health concerns and is among the top ten causes of death from a single infectious agent.
- Trial name
- Elderly-USR (NCT07076225)
- Testing
- Bedaquiline (B), Sitafloxacin (S), Linezolid (L)
- Volunteers
- 300 people
- Sponsor
- Shenzhen Third People's Hospital
Allergic Rhinitis, Asthma
Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
The investigators propose the development of a range of nasal spray challenge models to study the way the nose can respond to different types of nasal challenge that elicit different forms of inflammation.
- Conditions
- Allergic Rhinitis, Asthma, Latent Tuberculosis
- Trial name
- NCT02090374
- Testing
- Poly ICLC, Poly I:C, R848
- Where
- United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Tuberculosis
Taima TB: 3HP Study
This phase IV clinical study trial will be conducted among persons who require treatment for LTBI treatment in Iqaluit, Nunavut and Ottawa, Ontario.
- Trial name
- NCT02689089
- Testing
- 3HP
- Where
- Canada
- Volunteers
- 182 people
- Sponsor
- Ottawa Hospital Research Institute
HIV Infected Population With Latent Tuberculosis
Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers
People with human immunodeficiency virus (HIV) often take several medicines to control HIV. Dolutegravir and darunavir boosted with cobicistat are HIV medicines that people may take.
- Trial name
- NCT02771249
- Testing
- rifapentene (RPT), darunavir/cobicistat (DRV/c), Isoniazid (INH)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Latent Tuberculosis Infection, Tuberculosis
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
This is a prospective cohort study of persons tested for latent tuberculosis infection at either high risk for exposure to Mycobacterium tuberculosis or high risk for progression to tuberculosis disease.
- Trial name
- NCT01622140
- Where
- 10 sites in United States
- Volunteers
- 21,334 people
- Sponsor
- Centers for Disease Control and Prevention
Multi-drug Resistant Tuberculosis
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis
PandrTB is a study of the pharmacokinetics(PK) and pharmacodynamics(PD) of bedaquiline, delamanid, clofazimine, linezolid, moxifloxacin, levofloxacin and pyrazinamide used in novel combinations to treat multidrug-resistant…
- Trial name
- PandrTB (NCT03827811)
- Where
- 7 sites in Kazakhstan, Lesotho and 4 more
- Volunteers
- 625 people
- Sponsor
- University of Cape Town
Sporotrichosis, Chromomycosis
A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.
In Costa Rica there are some descriptive studies of some of these rare infectious diseases (sporotrichosis, chromomycosis and mycetomas); however, there are no recent published reports.
- Conditions
- Sporotrichosis, Chromomycosis, Actinomycosis, Nocardiosis
- Trial name
- NCT06523998
- Where
- 3 sites in Costa Rica
- Volunteers
- 95 people
- Sponsor
- Caja Costarricense de Seguro Social
Diabetes Mellitus, Tuberculosis
Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus
Diabetes mellitus (DM) increases susceptibility to Tuberculosis (TB) and worsens TB patient outcomes. The number of patients with combined TB and DM now outnumbers that of combined TB and HIV and it has been estimated that 15-30%…
- Trial name
- PROTID (NCT04600167)
- Testing
- Isoniazid and Rifapentine (INH-RPT)
- Where
- 4 sites in Tanzania, Uganda
- Volunteers
- 3,000 people
- Sponsor
- Dr. Nyanda Elias Ntinginya
Chronic Liver Disease With Tuberclosis
Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease
During the Study: Subject is required to visit every week for the first 2 months and then every month till completion of study or as and when required The usual symptomatic and supportive treatment of Chronic Liver Disease…
- Trial name
- NCT01677871
- Testing
- 2HRZE/4HR, 2HRLE/4HR, 9HLE
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
HIV Infections, Tuberculosis
Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
Successful therapy of both tuberculosis and HIV disease share similar problems: pill burden, drug interaction, adherence challenge and toxicity.
- Trial name
- NCT00115609
- Testing
- efavirenz, tenofovir DF, emtricitabine
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Tuberculosis Diagnosis
Evaluation of Different Diagnostic Methods of Tuberculosis in Assiut University Hospitals
Detection of sensitivity and specificity of microscopic examination and Molecular studies using polymerase chain reaction (PCR) Mycobacterium tuberculosis (MTB)/ non tuberculous mycobacterium (NTM) MDR-TB compared to culture…
- Trial name
- NCT06666972
- Testing
- PCR MTB/NTM
- Volunteers
- 166 people
- Sponsor
- Assiut University
Tuberculosis, Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00810407
- Testing
- rifabutin
- Volunteers
- 628 people
- Sponsor
- Pfizer
Tuberculosis, Pre-XDR-TB
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
BEAT Tuberculosis is a phase 3, open label, multi-centre, randomized controlled trial. The purpose of this trial is to compare the efficacy and safety of a Study Strategy consisting of 6 months of bedaquiline (BDQ), delamanid…
- Conditions
- Tuberculosis, Pre-XDR-TB, Extensively Drug-Resistant Tuberculosis, Multi Drug Resistant Tuberculosis
- Trial name
- NCT04062201
- Testing
- Bedaquiline Oral Tablet, Linezolid Oral Tablet, Delamanid in Oral Dosage Form
- Where
- 2 sites in South Africa
- Volunteers
- 402 people
- Sponsor
- Wits Health Consortium (Pty) Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.